Active broad market exchange-traded funds at mid-day:
Financial Select Sector SPDR (
): +0.59%, with a new 52-week high of $17.80
SPDR S&P 500 ETF Trust (
): +0.18%, hit a 52 week high of $152.07
iShares MSCI Emerging Markets Index (
iPath S&P 500 VIX ST Futures ETN (
): -1.15%, with a new 52-week low of $22.33
PowerShares QQQ Trust, Series 1(
Broad Market Indicators
Broad-market exchange-traded funds, including SPY, IWM, IVV and
others, are firmer. Actively traded PowerShares QQQ (
) is down 0.15%.
U.S. stocks have turned positive in the session's half,
following a clarification from a G7 official, who said the G7's
earlier statement was misinterpreted and that the upcoming meeting
will not target exchange rates. The ministers and governors of G7
said that it will continue to use domestic instruments to achieve
their respective domestic objectives.
Also providing a lift to market sentiment, the Kansas City
Federal Reserve's Esther L. George's commented that the U.S.
economy remains uneven, but is optimistic that it is recovering
faster than expected. Still ahead, the January Treasury Budget will
be released at 2 PM ET, while President Barack Obama's State of the
Union address will be given after the close of today's regular
Winners and Losers
Select Financial Sector SPDRs (
) is up 0.59%, touching a new 52-week high of $17.80. Direxion
Daily Financial Bull 3X shares (FAS) is up 1.77%, with new 52-week
high of $152.31. Its bearish counterpart, FAZ, is down 1.52%, with
a new 52-week low of $11.67.
Among financial actives, Barclays (BCS) is up 8.39% and pushed
to a fresh new 52-week high of $20.55 after it said it would slash
thousands of jobs. According to Dow Jones Newswires, the bank will
cut 3,700 jobs and narrow its focus to three key locations.
Technology Select Sector SPDR ETF (XLK), off 0.23%; iShares Dow
Jones US Technology ETF (IYW), down 0.36%; iShares S&P North
American Technology ETF (IGM), up 0.08%, near its 52-week high; and
iShares S&P North American Technology-Software Index (IGV) up
Among semiconductor ETFs, SPDR S&P Semiconductor (XSD) is up
0.45% while Semiconductor Sector Index Fund (SOXX) is off
SPDR S&P International Technology Sector ETF (IPK) is down
0.22% but is near its 52-week high.
In sector news, Level 3 Communications (LVLT) is now down 10.58%
after the company reported Q4 revenue of $1.61 bln, just ahead of
the analyst consensus of $1.60 bln on Capital IQ and up from $1.579
bln a year ago. EPS loss was $0.16, vs. expectations of a loss of
$0.07 per share, if comparable. Shares closed at $24.66.
Dow Jones U.S. Energy Fund (IYE) is up 0.2% while Energy Select
Sector SPDR (XLE) is up 0.26%. Both energy ETFs are near their
In sector news, Gran Tierra Energy Inc. (GTE) is now up 7.68%
after the company provided updates for its exploration drilling in
Peru and appraisal drilling in Colombia.
Crude was up 0.39%; natural gas was down 0.95%. United States
Oil Fund (USO) is up 0.54%. United States Natural Gas Fund (UNG) is
Gold was up 0.18% and silver was up 0.47%. Among rare metal
funds, SPDR Gold Trust (GLD) is up 0.15%; iShares Silver Trust
(SLV) is up 0.13%.
Consumer ETFs are mostly lower but near their 52-week highs:
Consumer Staples Select Sector SPDR (XLP), down 0.21%; iShares Dow
Jones US Consumer Goods (IYK), up 0.02%; and Vanguard Consumer
Staples ETF (VDC), down 0.15%.
In sector news, Avon Products (AVP) is up 19.13% after it
reported Q4 revs of $2.99 bln, in line with the analyst consensus
of $2.99 bln on Capital IQ. EPS was $0.37, vs. expectations of
$0.27 per share.
Power Play -
Healthcare ETFs are dipping lower, but still at the higher end
of their 52-week ranges: Health Care SPDR (XLV), down 0.05%;
Vanguard Health Care ETF (VHT), down 0.06%; and iShares Dow Jones
US Healthcare (IYH), down 0.11%. Biotech ETF iShares NASDAQ
Biotechnology Index (IBB) is down 0.21%.
In corporate news, StemCells (STEM) is now up 20.97%, trimming
earlier gains, after it announced that the 12-month data from the
first patient cohort in the company's Phase I/II clinical trial of
its proprietary HuCNS-SC product candidate (purified human neural
stem cells) for chronic spinal cord injury continued to demonstrate
a favorable safety profile, and showed that the considerable gains
in sensory function observed in two of the three patients at the
six-month assessment have persisted.
The third patient remains stable. By completing the twelve-month
assessment, the first patient cohort has now completed the trial,
and has entered into a separate follow-up study for long-term
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.